Search
- Page Path
- HOME > Search
- JYNNEOS vaccine safety monitoring in the Republic of Korea, 2022: a cross-sectional study
- Jaeeun Lee, Seunghyun Lewis Kwon, Jinhee Park, Hyuna Bae, Hyerim Lee, Geun-Yong Kwon
- Osong Public Health Res Perspect. 2023;14(5):433-438. Published online October 18, 2023
- DOI: https://doi.org/10.24171/j.phrp.2023.0182
- 1,579 View
- 51 Download
- 4 Web of Science
- 3 Crossref
-
Graphical Abstract
Abstract
PDF 
- Objectives
With the recent global mpox outbreak, the JYNNEOS vaccine (Modified Vaccinia Ankara-Bavarian Nordic) was developed as a third-generation smallpox vaccine and initially favored for mpox immunization. Vaccine-associated side effects contribute to vaccine hesitancy. Consequently, tracking adverse events post-immunization is crucial for safety management. This study used data from the national active vaccine safety surveillance conducted in Korea from August 25 to November 24, 2022 to detect potential safety signals and adverse events. Methods: Data on health conditions following vaccination were gathered from web-based surveys and reported via active surveillance through the Immunization Registry Information System. This follow-up system functioned via a text message link, surveying adverse events and health conditions beginning on the second day post-vaccination. Information about specific adverse events, including both local and systemic reactions, was collected. Results: The study included 86 healthcare workers who had received at least 1 dose of the JYNNEOS vaccine. Among the respondents, 79.1% reported experiencing at least 1 adverse event, with the majority being local reactions at the injection site. The incidence of adverse events was higher following the first dose (67.9%) than after the second dose (34.4%). The most frequently reported adverse event for both doses was mild pain at the injection site. Conclusion: The study provides crucial information on the safety of the JYNNEOS vaccine, demonstrating that most adverse events were manageable and predominantly localized to the injection site. Nonetheless, additional research is needed on the safety of various vaccine administration techniques and the vaccine’s effects on broader demographics. -
Citations
Citations to this article as recorded by
- Adverse Reactions After Intradermal Vaccination With JYNNEOS for Mpox in Korea
So Yun Lim, Yu Mi Jung, Yeonjae Kim, Gayeon Kim, Jaehyun Jeon, BumSik Chin, Min-Kyung Kim
Journal of Korean Medical Science.2024;[Epub] CrossRef - First Nationwide Mpox Vaccination Program in the Republic of Korea: Implications for an Enhanced Public Health Response
Seunghyun Lewis Kwon, Minju Song, Wonkyung Lee, Jeeyeon Shin, Su-Yeon Lee, Sang-Gu Yeo, Minjeong Kim, Sanggyun Jeong, Joonku Park, Dongwoo Lee, Sookyoung Lim
Journal of Korean Medical Science.2024;[Epub] CrossRef - Global perspectives on smallpox vaccine against monkeypox: a comprehensive meta-analysis and systematic review of effectiveness, protection, safety and cross-immunogenicity
Hao Liu, Wenjing Wang, Yang Zhang, Fuchun Wang, Junyi Duan, Tao Huang, Xiaojie Huang, Tong Zhang
Emerging Microbes & Infections.2024;[Epub] CrossRef
- Adverse Reactions After Intradermal Vaccination With JYNNEOS for Mpox in Korea
- A Healthcare-Associated Outbreak of HCV Genotype 2a at a Clinic in Seoul
- Siwon Choi, Hyerim Lee, Hyungmin Lee, Yoon-Seok Chung
- Osong Public Health Res Perspect. 2021;12(1):3-12. Published online February 23, 2021
- DOI: https://doi.org/10.24171/j.phrp.2021.12.1.02
- 6,183 View
- 255 Download
-
Abstract
PDF
Objectives An epidemiological investigation was conducted into a hepatitis C virus (HCV) outbreak at an outpatients clinic in Seoul (2011–2012). The aim of the study was to analyze the scale of infection, identify the source of infection, and route of transmission to prevent hepatitis C transmission in the future.
Methods A retrospective study of the outpatients and health care workers (
n = 7,285) in the target outpatient clinic during 2011–2012 was conducted. The history of the study population infection with hepatitis C, electronic medical records, field visits, and health care worker interviews were examined for the period between March 1st, 2006 and March 25th, 2016. The blood samples were collected and tested for anti-HCV antibodies, HCV RNA and HCV gene in 2016.Results The rate of anti-HCV positive results was 4.4% in the study population. The risk factors associated with an anti-HCV positive result were ≥ 10 clinic visits, and receiving an invasive procedure including a nerve block and a block of the peripheral branch of the spinal nerve (
p < 0.05). There were 112 HCV RNA positive cases out of 320 anti-HCV positive test result cases, amongst which 100 cases had the dominant HCV genotype 2a which formed either 1 cluster (n = 56) or 2 clusters (n = 25). This result indicated exposure to a high-association infection source.Conclusion Anti-HCV antibodies and genotypic analysis showed an epidemiological association between the outbreak of HCV and invasive procedures performed (2011–2012) at an outpatients clinic in Seoul.
First
Prev
